ATE468534T1 - Verwendung von biomarkern zum nachweis von eierstockkrebs - Google Patents

Verwendung von biomarkern zum nachweis von eierstockkrebs

Info

Publication number
ATE468534T1
ATE468534T1 AT03767259T AT03767259T ATE468534T1 AT E468534 T1 ATE468534 T1 AT E468534T1 AT 03767259 T AT03767259 T AT 03767259T AT 03767259 T AT03767259 T AT 03767259T AT E468534 T1 ATE468534 T1 AT E468534T1
Authority
AT
Austria
Prior art keywords
ovarian cancer
biomarkers
detecting ovarian
subject
cancer status
Prior art date
Application number
AT03767259T
Other languages
English (en)
Inventor
Daniel Chan
Zhen Zhang
Eric Fung
Xiao-Ying Meng
Original Assignee
Univ Johns Hopkins
Ciphergen Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Ciphergen Biosystems Inc filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE468534T1 publication Critical patent/ATE468534T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/807—Gas detection apparatus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
    • Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03767259T 2002-08-06 2003-08-05 Verwendung von biomarkern zum nachweis von eierstockkrebs ATE468534T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40183702P 2002-08-06 2002-08-06
US44172703P 2003-01-21 2003-01-21
US46034203P 2003-04-04 2003-04-04
PCT/US2003/024659 WO2004013609A2 (en) 2002-08-06 2003-08-05 Use of biomarkers for detecting ovarian cancer

Publications (1)

Publication Number Publication Date
ATE468534T1 true ATE468534T1 (de) 2010-06-15

Family

ID=31499343

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03767259T ATE468534T1 (de) 2002-08-06 2003-08-05 Verwendung von biomarkern zum nachweis von eierstockkrebs

Country Status (15)

Country Link
US (3) US7605003B2 (de)
EP (1) EP1540010B8 (de)
JP (1) JP4644123B2 (de)
KR (2) KR101107765B1 (de)
CN (3) CN101692090B (de)
AT (1) ATE468534T1 (de)
AU (3) AU2003256858B2 (de)
CA (1) CA2493817A1 (de)
DE (1) DE60332639D1 (de)
DK (1) DK1540010T3 (de)
ES (1) ES2346202T3 (de)
HK (1) HK1200915A1 (de)
IL (3) IL166118A (de)
NZ (1) NZ562192A (de)
WO (2) WO2004013609A2 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598325B2 (en) 2002-03-11 2013-12-03 Janusz B. Pawliszyn Solid-phase microextraction coatings and methods for their preparation
US20090026122A1 (en) * 2002-03-11 2009-01-29 Janusz Biocompatible solid-phase microextraction coatings and methods for their preparation
US9870907B2 (en) 2002-03-11 2018-01-16 Jp Scientific Limited Probe for extraction of molecules of interest from a sample
JP4381820B2 (ja) * 2002-03-11 2009-12-09 ポーリスツィン、ジャヌス・ビー 生体組織検査用マイクロ抽出装置
US7232689B2 (en) * 2002-03-11 2007-06-19 Pawliszyn Janusz B Calibration procedure for investigating biological systems
US9733234B2 (en) 2002-03-11 2017-08-15 Jp Scientific Limited Probe for extraction of molecules of interest from a sample
SE0300454D0 (sv) * 2003-02-19 2003-02-19 Aamic Ab Nozzles for electrospray ionization and methods of fabricating them
US7007710B2 (en) * 2003-04-21 2006-03-07 Predicant Biosciences, Inc. Microfluidic devices and methods
US20040236603A1 (en) * 2003-05-22 2004-11-25 Biospect, Inc. System of analyzing complex mixtures of biological and other fluids to identify biological state information
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US20050100967A1 (en) * 2003-07-11 2005-05-12 Science & Technology Corporation @ Unm Detection of endometrial pathology
WO2005055812A2 (en) * 2003-12-05 2005-06-23 Ciphergen Biosystems, Inc. Serum biomarkers for chagas disease
JP4912894B2 (ja) 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
WO2005098446A2 (en) * 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
KR100624420B1 (ko) * 2004-04-10 2006-09-19 삼성전자주식회사 마이크로어레이에 대한 정보가 스팟의 형태로 저장되어있는 마이크로어레이, 그를 제조하는 방법 및 그를이용하는 방법
US20050244973A1 (en) * 2004-04-29 2005-11-03 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
US7670792B2 (en) 2004-07-14 2010-03-02 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
EP2261672B1 (de) * 2004-07-14 2014-09-03 The Regents of The University of California Biomarker für den frühzeitigen Nachweis von Ovarialkarzinom
US9488655B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
WO2012047930A2 (en) 2010-10-04 2012-04-12 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
MX2007001479A (es) 2004-08-13 2007-07-25 Indivumed Gmbh Uso de transtiretina como un biomarcador para adenoma y/o carcinoma colorrectal; metodo para deteccion y sistema de prueba.
WO2006034032A2 (en) * 2004-09-17 2006-03-30 The Johns Hopkins University Biomarkers for breast cancer
JP5069214B2 (ja) * 2005-03-11 2012-11-07 ヴァーミリオン インコーポレイテッド 卵巣癌及び子宮内膜癌のバイオマーカー：ヘプシジン
US20070087387A1 (en) * 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
EP1877795A4 (de) * 2005-05-02 2010-04-28 Brigham & Womens Hospital Diagnostische profilerstellung von serumantikörpern
CN101243319B (zh) * 2005-06-22 2016-01-06 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
US8465929B2 (en) * 2005-06-24 2013-06-18 Vermillion, Inc. Biomarkers for ovarian cancer
AU2006261904B2 (en) * 2005-06-24 2012-05-31 Aspira Women’s Health Inc. Biomarkers for ovarian cancer: beta-2 microglobulin
AT502227B1 (de) * 2005-08-08 2007-08-15 Vitateq Biotechnology Gmbh Verfahren zur diagnose von tumoren
WO2007022248A2 (en) * 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methods of detection of cancer using peptide profiles
WO2007030949A2 (en) * 2005-09-15 2007-03-22 Val-Chum, S.E.C. Methods of diagnosing ovarian cancer and kits therefor
CN101473041B (zh) * 2006-01-04 2017-11-14 富士瑞必欧美国公司 He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用
WO2008051260A1 (en) * 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
EP1987360B1 (de) * 2006-01-27 2012-03-07 Tripath Imaging, Inc. Verfahren zur identifizierung von patienten mit erhöhter wahrscheinlichkeit des auftretens eines ovarialkarzinoms und zusammensetzungen dafür
JP2009531712A (ja) * 2006-03-23 2009-09-03 デ グスマン ブレイヤー、エメリタ アポリポタンパク質フィンガープリント技術
US20090263842A1 (en) * 2006-03-24 2009-10-22 Expression Pathology Method of assessing the metastatic status of a primary tumor
US7867775B2 (en) 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US7906342B2 (en) 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858389B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
US7858390B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
JP2007315941A (ja) * 2006-05-26 2007-12-06 Univ Of Miyazaki 植物品種判定装置、植物品種判定方法及び植物品種判定用プログラム
WO2008060376A2 (en) * 2006-10-04 2008-05-22 The Johns Hopkins University Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
WO2008048508A2 (en) * 2006-10-13 2008-04-24 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
EP2682746B1 (de) * 2007-02-01 2017-05-24 Phenomenome Discoveries Inc. Verfahren zur Diagnose des Gesundheitszustands von Eierstockkrebs und der Gefahr von Gesundheitszuständen von Eierstockkrebs
JP5298858B2 (ja) 2007-02-16 2013-09-25 株式会社島津製作所 上皮性卵巣癌の組織型識別マーカー、及びそれを用いた組織型に基づく上皮性卵巣癌の罹患の識別法
US8221984B2 (en) * 2007-03-27 2012-07-17 Vermillion, Inc. Biomarkers for ovarian cancer
EP2152417B1 (de) 2007-05-04 2018-07-11 Opko Diagnostics, LLC Vorrichtung und methode für analysen in mikrofluidsysteme
CN101855553B (zh) 2007-06-29 2014-06-11 韩国安国药品株式会社 卵巢癌的预测标记
CA2694112A1 (en) * 2007-07-20 2009-01-29 The University Of Utah Research Foundation Identification and quantification of biomarkers for evaluating the risk of preterm birth
WO2009058331A2 (en) 2007-10-29 2009-05-07 Vermilllion, Inc. Biomarkers for the detection of early stage ovarian cancer
US20090123932A1 (en) * 2007-11-09 2009-05-14 Anne-Marie Mes-Masson Quantitative test to detect disease progression markers of epithelial ovarian cancer patients
US8642347B2 (en) * 2008-01-31 2014-02-04 The Brigham And Women's Hospital, Inc. Urinary CA125 peptides as biomarkers of ovarian cancer
US8476026B2 (en) * 2008-04-01 2013-07-02 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
WO2010087999A1 (en) 2009-02-02 2010-08-05 Claros Diagnostics, Inc. Structures for controlling light interaction with microfluidic devices
US8704194B2 (en) * 2010-04-12 2014-04-22 Canon Kabushiki Kaisha Information acquiring apparatus and information acquiring method for acquiring mass-related information
US20120016598A1 (en) * 2010-05-21 2012-01-19 Bruker Daltonik Gmbh Normalization of mass spectra acquired by mass spectrometric imaging
WO2012019000A2 (en) * 2010-08-04 2012-02-09 On-Q-ity Biomarkers for the identification monitoring and treatment of ovarian cancer
AU2011316844A1 (en) * 2010-10-22 2013-06-06 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
GB2503148A (en) * 2011-02-24 2013-12-18 Vermillion Inc Biomarker panels diagnostic methods and test kits for ovarian cancer
AU2012226530B2 (en) 2011-03-08 2016-12-01 King Abdullah University Of Science And Technology Molecular biomarker set for early detection of ovarian cancer
WO2013016700A1 (en) * 2011-07-27 2013-01-31 The Research Foundation Of State University Of New York Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc
JP6078067B2 (ja) 2011-08-29 2017-02-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 炎症誘発性状態の治療および予防のためのｈｄｌ関連分子の使用
WO2013116455A1 (en) * 2012-01-31 2013-08-08 Bio-Rad Laboratories, Inc. Improved sensitivity and specificity for ovarian cancer
CN108108590A (zh) 2012-03-05 2018-06-01 阿克蒂克合伙公司 分析系统和方法
US20160291025A1 (en) * 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
US20150153348A1 (en) * 2013-12-04 2015-06-04 Vermillion, Inc. BIOMARKERS FOR OVARIAN CANCER: Beta 2 MICROGLOBULIN
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
MX392384B (es) 2014-03-28 2025-03-24 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
CA2958745C (en) 2014-08-29 2023-09-19 Biomerieux, Inc. Maldi-tof mass spectrometers with delay time variations and related methods
EP3253800B1 (de) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostata-antigenstandards und verwendungen davon
ES2955883T3 (es) 2015-06-19 2023-12-07 Sera Prognostics Inc Pares de biomarcadores para la predicción del parto prematuro
EP3423186A4 (de) 2016-03-02 2019-10-23 JP Scientific Limited Festphasen-mikroextraktionsbeschichtung
EP3455870B1 (de) 2016-05-10 2024-10-02 JP Scientific Limited System und verfahren zur desorption und erkennung eines auf einer festphasenmikroextraktionsvorrichtung sorbierten analyten
CN106520924A (zh) * 2016-10-14 2017-03-22 浙江大学 一种用于检测卵巢癌的引物组及检测方法
CN106544421B (zh) * 2016-10-21 2020-05-08 武汉科技大学 Spag6基因作为卵巢肿瘤诊断和治疗标志物的用途
AU2018317902B2 (en) 2017-08-18 2025-02-20 Sera Prognostics, Inc. Pregnancy clock proteins for predicting due date and time to birth
BR112021011194A2 (pt) * 2019-01-16 2021-08-31 Regeneron Pharmaceuticals, Inc. Método e sistema de identificar e quantificar a fragmentação do anticorpo
KR20240137114A (ko) 2019-08-05 2024-09-19 시어 인코퍼레이티드 샘플 제조, 데이터 생성, 및 단백질 코로나 분석을 위한 시스템 및 방법
CN113125762A (zh) * 2019-12-31 2021-07-16 瑞博奥(广州)生物科技股份有限公司 一种检测女性恶性肿瘤标志物的检测芯片及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584278A (en) * 1982-03-19 1986-04-22 University Of Rochester Antigen derived from human ovarian tumors and radioimmunoassay using the antigen
US4921790A (en) * 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
AU6031090A (en) * 1989-07-31 1991-03-11 University Of British Columbia, The Monoclonal antibodies against a tumor-associated antigen
US5366866A (en) * 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
WO1994028418A1 (en) * 1993-05-28 1994-12-08 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US5800347A (en) * 1995-11-03 1998-09-01 The General Hospital Corporation ROC method for early detection of disease
US5824555A (en) * 1996-05-30 1998-10-20 The Cleveland Clinic Foundation Method of detecting gynecological carcinomas
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
KR100713786B1 (ko) 1999-04-27 2007-05-07 바이오 래드 래버러토리스 인코오포레이티드 기체상 이온 분광계용 탐침
WO2001033228A2 (en) * 1999-11-03 2001-05-10 Oncotech, Inc. Cancer diagnosis employing cell-sorting and gene-profiles
AU2001288853A1 (en) * 2000-09-07 2002-03-22 The Brigham And Women's Hospital, Inc. Methods of detecting cancer based on prostasin
JP2004512540A (ja) * 2000-11-01 2004-04-22 マウント・サイナイ・ホスピタル 卵巣癌の検出
WO2002042733A2 (en) 2000-11-16 2002-05-30 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
AU2003235749A1 (en) 2002-01-07 2003-07-24 John Hopkins University Biomarkers for detecting ovarian cancer
US20040153249A1 (en) * 2002-08-06 2004-08-05 The Johns Hopkins University System, software and methods for biomarker identification
US20060073525A1 (en) 2002-08-28 2006-04-06 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
AU2002951346A0 (en) 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
US7288383B2 (en) 2003-01-15 2007-10-30 The Brigham And Women's Hospital, Inc. Eosinophil-derived neurotoxin as a marker for ovarian cancer

Also Published As

Publication number Publication date
IL252832A0 (en) 2017-08-31
CN103969449A (zh) 2014-08-06
ES2346202T3 (es) 2010-10-13
HK1200915A1 (en) 2015-08-14
WO2004013609A8 (en) 2005-03-10
CN101692090B (zh) 2014-06-25
CN103969449B (zh) 2016-11-23
US20140038852A1 (en) 2014-02-06
WO2004012588A3 (en) 2005-12-15
CN101692090A (zh) 2010-04-07
CA2493817A1 (en) 2004-02-12
AU2003257207A1 (en) 2004-02-23
EP1540010B1 (de) 2010-05-19
EP1540010A2 (de) 2005-06-15
WO2004012588A2 (en) 2004-02-12
IL220734A (en) 2017-06-29
US20050059013A1 (en) 2005-03-17
WO2004013609A3 (en) 2005-04-14
KR101107765B1 (ko) 2012-01-25
CN100558909C (zh) 2009-11-11
KR20050062518A (ko) 2005-06-23
DE60332639D1 (de) 2010-07-01
WO2004013609A2 (en) 2004-02-12
EP1540010B8 (de) 2010-07-14
NZ562192A (en) 2009-07-31
IL252832B (en) 2019-10-31
JP4644123B2 (ja) 2011-03-02
IL166118A0 (en) 2006-01-15
US20110033867A1 (en) 2011-02-10
EP1540010A4 (de) 2007-01-17
HK1076489A1 (en) 2006-01-20
CN1675372A (zh) 2005-09-28
AU2010202525A1 (en) 2010-07-08
AU2003256858B2 (en) 2010-07-01
KR20110019357A (ko) 2011-02-25
JP2006512586A (ja) 2006-04-13
US7605003B2 (en) 2009-10-20
AU2003256858A1 (en) 2004-02-23
DK1540010T3 (da) 2010-07-26
IL166118A (en) 2012-07-31
AU2003257207A8 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
DE60332639D1 (de) Verwendung von biomarkern zum nachweis von eierstockkrebs
WO2005098446A3 (en) Biomarkers for ovarian cancer
WO2004099432A3 (en) Identification of biomarkers for detecting pancreatic cancer
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
MX340856B (es) Sistema y metodos que determinan concentracion de analito utilizando amperometria resuelta en tiempo.
WO2007038754A3 (en) Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
ATE393240T1 (de) Verfahren zum nachweis von prostatakrebs
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
ATE550649T1 (de) Testvorrichtung für analyten mit vielseitiger verwendungsmöglichkeit
DE602007010032D1 (de) Immunoassay mit mehreren analyten
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
PL1776587T3 (pl) Zastosowanie C3A i jego pochodnych jako biomarkera do leczenia gruczolaka i/lub raka jelita grubego; metody diagnostyczne i testy z ich użyciem
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
TW200745551A (en) Device and methods for detecting and quantifying one or more target agents
WO2003091695A3 (en) Identification of biomarkers for detecting prostate cancer
WO2005094332A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
WO2005040759A3 (en) Apparatus and methods for detecting target analyte
WO2003076896A3 (en) Use of biomarkers to detect breast cancer
GB2441694A (en) A building crack monitoring device
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
WO2009082533A3 (en) Method of identification of petroleum compounds using frequency mixing on surfaces
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
ATE528640T1 (de) Detektionssysteme und -verfahren für flüssigkeitsgekoppelte defekte
ATE412181T1 (de) Verbessertes verfahren zur diagnose des akuten koronarsyndroms

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties